Novo, General Atlantic and Goldman Sachs Asset Management led a Series C round in LePure Biotech.

Investment companies Novo, General Atlantic and Goldman Sachs Asset Management led a Series C round in LePure Biotech, a biopharma solutions provider, with participation from Highlight Capital, Bayland Capital and HM Capital. Financial terms were not disclosed. LePure plans on using this funding to accelerate product innovation, promote overseas expansion, and enhance the Company’s competitiveness and influence in the global industrial chain.